v3.24.1.u1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:    
Total revenues $ 36,598 $ 64,782
Cost of revenues:    
Total cost of revenues 17,708 19,089
Gross profit 18,890 45,693
Operating expenses:    
Research and development 50,611 40,741
Sales and marketing 10,171 9,145
General and administrative 25,541 26,308
Total operating expenses 86,323 76,194
Loss from operations (67,433) (30,501)
Other income:    
Gain on equity investments 0 147,322
Change in fair value 8,137 35,737
Other income 5,028 2,937
Total other income 13,165 185,996
(Loss) income before income taxes (54,268) 155,495
Income tax expense 456 26,359
Net (loss) income $ (54,724) $ 129,136
Earnings Per Share [Abstract]    
Net (loss) income per share of common and limited common stockholders, basic: (in USD per share) $ (0.76) $ 1.81
Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, basic: (in shares) 72,291,134 71,467,097
Net (loss) income per share of common and limited common stockholders, diluted: (in USD per share) $ (0.76) $ 1.75
Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, diluted: (in shares) 72,291,134 73,818,611
Software products and services    
Revenues:    
Total revenues $ 33,415 $ 32,213
Cost of revenues:    
Total cost of revenues 7,976 7,115
Drug discovery    
Revenues:    
Total revenues 3,183 32,569
Cost of revenues:    
Total cost of revenues $ 9,732 $ 11,974